This study tests a drug called mirvetuximab soravtansine in people with a specific type of recurrent ovarian cancer that has high levels of a protein called folate receptor alpha. The drug delivers chemotherapy directly to cancer cells to try to slow or stop the cancer from growi…
Phase: PHASE2 • Sponsor: AGO Research GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC